Clinical Trial Update: Persistence of Antibodies After Meningococcal Vaccine PF-06866681 in Healthy Children [Phase 3]

View source ↗

Summary

Phase 3 trial update evaluating persistence of antibodies after meningococcal vaccine PF-06866681 in healthy children; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Infections

Drugs mentioned

• PF-06866681

Snippet

Sponsor: Pfizer | Conditions: Infections, Meningococcal | Phase 3 | Status: COMPLETED | Results posted: 2019-06-17